Novo Nordisk loses more ground in obesity market - Financial Times

[unable to retrieve full-text content]

1. Novo Nordisk loses more ground in obesity market  Financial Times
2. Ozempic maker struggles as it loses ground to rivals in weight-loss market  The Guardian
3. Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mount  CNBC
4. Novo Nordisk's Medicare deal takes heat off Wegovy slowdown  Reuters
5. Novo Nordisk cuts sales and profits guidance amid obesity drug competition  The Independent

https://news.google.com/rss/articles/CBMicEFVX3lxTE5XbUZvNUZVQ1BrcHdMeXhITmwwaU9sWEdyUjJxcGpSS1pIaENjaDVJZHpQckN1ajAxSEVjQTlJMGtkU0lNUjFXb2hzN2tCMEJmR3owYU1FcUd6Qm94a1UyQ3pvOEpkUzlEV1RzQm5TamQ?oc=5

2025-11-05 10:47:31Z
CBMicEFVX3lxTE5XbUZvNUZVQ1BrcHdMeXhITmwwaU9sWEdyUjJxcGpSS1pIaENjaDVJZHpQckN1ajAxSEVjQTlJMGtkU0lNUjFXb2hzN2tCMEJmR3owYU1FcUd6Qm94a1UyQ3pvOEpkUzlEV1RzQm5TamQ